Well Life Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-07-2024
- Paid Up Capital ₹ 0.10 M
as on 06-07-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
as on 06-07-2024
- Revenue 75.43%
(FY 2020)
- Profit 80.62%
(FY 2020)
- Ebitda 91.27%
(FY 2020)
- Net Worth 30.76%
(FY 2020)
- Total Assets 23.82%
(FY 2020)
About Well Life Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 M.
Jugal Shah, Jay Savla, Bhavini Jay, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239MH2010PTC203805
- Company No.
203805
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Well Life Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jugal Shah  | Director | 12-Nov-2019 | Current |
| Jay Savla | Director | 29-May-2015 | Current |
| Bhavini Jay | Director | 29-May-2015 | Current |
| Dhiraj Gupta | Additional Director | 13-Apr-2024 | Current |
| Anshu Gupta | Director | 08-Jun-2010 | Current |
Financial Performance of Well Life Pharmaceuticals.
Well Life Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 75.43% increase. The company also saw a substantial improvement in profitability, with a 80.62% increase in profit. The company's net worth Soared by an impressive increase of 30.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Well Life Pharmaceuticals?
In 2020, Well Life Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nandan Pharma Private LimitedActive 11 years 11 monthsDhiraj Gupta and Anshu Gupta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Cosmos Co-Op Bank Ltd Creation Date: 20 May 2015 | ₹3.00 M | Open |
How Many Employees Work at Well Life Pharmaceuticals?
Unlock and access historical data on people associated with Well Life Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Well Life Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Well Life Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
